Research Showcase summary – 2025
The primary focus of this study is to use new generation imaging modalities to evaluate structural features of the glaucoma filtration surgical (GFS) sites to distinguish parameters associated with surgical success and failure. The study will also evaluate secondary structural and vascular retinal changes seen after surgical intervention. This is of importance given GFS, specifically trabeculectomy and deep sclerectomy are prone to failure secondary to inadequate function within the surgical site (bleb). Wide variations in surgical technique exist in GFS with varying degrees of reported success. Read more…
Primary open angle glaucoma (POAG) is a progressive disease caused by raised eye pressure that leads to sight loss. In POAG eye pressure increases because the fluid inside your eye can’t drain out properly because the drainage tissue inside the eye is blocked by abnormal cells and scarring. Eventually, this high pressure can lead to the cells in your optic nerve and retina dying, which can cause permanent blindness. Reducing eye pressure is the only proven method to manage glaucoma, however it does not treat the underlying cause of the disease. Treatment is usually an eye drop that reduces the production of liquid within your eye, but often these eye drop therapies fail over time and the patient requires surgery. Therefore, there is a need to develop new therapies for glaucoma. Read more…
The eye pressure or intra-ocular pressure is the only treatable factor in glaucoma. Even when intra- ocular pressure is reduced and well controlled by your eye specialist some people with glaucoma can still show progressive visual field loss. Inflammation can drive glaucoma progression and damage the nerve tissue in the eye. In animal and human glaucoma tissues, inflammation activates a group of proteins called the ‘inflammasome’. We have developed an antibody which targets the inflammasome and switches off inflammation. In cells from human optic nerve head, we have switched off inflammation using this antibody. Read more…
The prevalence of glaucoma is increasing and so too is the demand for capacity within glaucoma services1. The Royal College of Ophthalmologists2 and College of Optometrists3 recently released new guidance on when to refer and treat patients at risk of narrow angle glaucoma. The guidance recommends a higher threshold of risk for both referral and treatment than what has been used before. The aims of these changes are: to provide clarity on who should be referred and treated; reduce unnecessary referrals to the hospital eye service, creating more capacity for higher risk patients; reducing unnecessary treatment for patients at lower risk of developing narrow angle closure glaucoma. Read more…
